5-(3,4-Dimethoxyphenyl)-7-(4-methoxyphenyl)imidazo[1,2-a]pyridine-8-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(3,4-Dimethoxyphenyl)-7-(4-methoxyphenyl)imidazo[1,2-a]pyridine-8-carbonitrile
• 化学式: C₂₃H₁₉N₃O₃
• 分子量: 385.4
• InChiKey: FSFOCWXLNMJZQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• NOVEL IMIDAZOPYRIDINE CARBONITRILE COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1222188A1

  公开（公告）日：2002-07-17
• [EN] NOVEL IMIDAZOPYRIDINE CARBONITRILE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES IMIDAZOPYRIDINE CARBONITRILE
  申请人：ASTRAZENECA AB

  公开号：WO2001025237A1

  公开（公告）日：2001-04-12

  The present invention relates to a selective inhibitor of mammalian osteoclast cell activity, processes for its preparation and pharmaceutical compositions comprising the same as well as methods of treatment, where said selective inhibitor is administered to a human or animal patient. Said selective inhibitor has been found to inhibit vacuolar H+-ATPase, such as vacuolar H+-ATPase in osteoclast cells, whereby it is therapeutically efficient against physiological disorders involving bone resorption. In an embodiment of the present invention, said selective inhibitor comprises an imidazopyridine carbonitrile compound with general formula (I).